Thromboembolic Events With Recombinant Activated Factor VII in Spontaneous Intracerebral Hemorrhage: Results From the Factor Seven for Acute Hemorrhagic Stroke (FAST) Trial
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Background and Purpose— Patients with intracerebral hemorrhage have a high risk of thromboembolic events (TEs) due to advanced age, hypertension, atherosclerosis, diabetes, and immobility. Use of recombinant activated factor VII (rFVIIa) could increase TEs in high-risk patients. Factor Seven for Acute Hemorrhagic Stroke (FAST) trial data were reviewed to define the frequency of and risk factors for TE with rFVIIa. Methods— Eight hundred forty-one patients presenting <3 hours after spontaneous intracerebral hemorrhage were randomized to 20 or 80 μg/kg of rFVIIa or placebo. Those with Glasgow Coma Scale score <5, planned early surgery, coagulopathy, or recent TE were excluded. Myocardial, cerebral, or venous TEs were subject to detailed reporting and expedited local review. Additionally, a blinded Data Monitoring Committee reviewed all electrocardiograms, centrally analyzed troponin I values, and CT scans. Results— There were 178 arterial and 47 venous TEs. Venous events were similar across groups. There were 49 (27%) arterial events in the placebo group, 47 (26%) in the 20-μg/kg group, and 82 (46%) in the 80 μg/kg group ( P =0.04). Of the myocardial events, 38 were investigator-reported and 103 identified by the Data Monitoring Committee. They occurred in 17 (6.3%) placebo and 57 (9.9%) rFVIIa patients ( P =0.09). Arterial TEs were associated with: receiving 80 μg/kg rFVIIa (OR=2.14; P =0.031), signs of cardiac or cerebral ischemia at presentation (OR=4.19; P =0.010), age (OR=1.14/5 years; P =0.0123), and prior use of antiplatelet agents (OR=1.83; P =0.035). Ischemic strokes possibly related to study drug occurred in 7, 5, and 8 patients in the placebo, 20 μg/kg, and 80-μg/kg groups, respectively. Conclusions— Higher doses of rFVIIa in a high-risk population are associated with a small increased risk of what are usually minor cardiac events. Demonstration of the ability of rFVIIa to improve outcome in future studies should be driven by its effectiveness in slowing bleeding outweighting the risk of a small increase in arterial TEs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Efficacy and Safety of Recombinant Activated Factor VII for Acute Intracerebral Hemorrhage
Mayer, S. A., Brun, N. C., Begtrup, K., Broderick, J., Davis, S., Diringer, M. N., Skolnick, B. E., & Steiner, T. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0707534 · Cited by 1,255
Self-citation
Cited by
Intracerebral haemorrhage: mechanisms of injury and therapeutic targets
Keep, R. F., Hua, Y., & Xi, G. (2012) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70104-7 · Cited by 1,308
Steiner, T., Salman, R. A.-S., Beer, R., Christensen, H., Cordonnier, C., Csiba, L., Forsting, M., Harnof, S., Klijn, C. J. M., Krieger, D., et al. (2014) · International Journal of Stroke · doi:10.1111/ijs.12309 · Cited by 813
Self-citationDemchuk, A. M., Dowlatshahi, D., Rodriguez-Luna, D., Molina, C. A., Blas, Y. S., Dzialowski, I., Kobayashi, A., Boulanger, J.-M., Lum, C., Gubitz, G., et al. (2012) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70038-8 · Cited by 642
Yaghi, S., Willey, J. Z., Cucchiara, B., Goldstein, J. N., Gonzales, N. R., Khatri, P., Kim, L. J., Mayer, S. A., Sheth, K. N., & Schwamm, L. H. (2017) · Stroke · doi:10.1161/str.0000000000000152 · Cited by 545
Self-citationMerino, J. G., & Warach, S. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2010.129 · Cited by 152
Metadata
- Authors
- Diringer, M. N., Skolnick, B. E., Mayer, S. A., Steiner, T., Davis, S. M., Brun, N. C., & Broderick, J. P.
- Venue
- Stroke
- Published
- 2010-01
- Volume
- 41
- Issue
- 1
- Pages
- 48-53
- ISSN
- 0039-2499 (ISSN-L)
- 1524-4628
- OpenAlex
- W2042961769
- Cited by
- 122
- References
- 1
- FWCI
- 8.63
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.